NOS3 and coronary artery disorder: In patients with coronary artery disease, treatment with the drug, atorvastatin (a well-documented cardioprotective, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor) reduces miR-222 expression in EPCs, leading to their increased mobilization via the eNOS-dependent pathway, confirming the mechanism suggested by our study [58].